Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Briacell Therapeutics stock

Learn how to easily invest in Briacell Therapeutics stock.

Briacell Therapeutics Corp is a biotechnology business based in the US. Briacell Therapeutics shares (BCTX) are listed on the NASDAQ and all prices are listed in US Dollars. Briacell Therapeutics employs 5 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Briacell Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Briacell Therapeutics stock price (NASDAQ: BCTX)

Use our graph to track the performance of BCTX stocks over time.

Briacell Therapeutics shares at a glance

Information last updated 2022-09-25.
Latest market close$5.37
52-week range$4.06 - $12.47
50-day moving average $6.92
200-day moving average $7.21
Wall St. target price$20.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.95

Buy Briacell Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Briacell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Briacell Therapeutics price performance over time

Historical closes compared with the close of $5.37 from 2022-09-29

1 week (2022-09-23) -8.36%
1 month (2022-09-01) -33.62%
3 months (2022-07-01) -11.68%
6 months (2022-04-01) -48.12%
1 year (2021-10-01) -34.03%
2 years (2020-09-27) N/A
3 years (2019-10-01) 10,640.00%
5 years (2017-09-27) 4,673.33%

Briacell Therapeutics financials

Gross profit TTM $0
Return on assets TTM -23.47%
Return on equity TTM -46.36%
Profit margin 0%
Book value $2.95
Market capitalisation $91.1 million

TTM: trailing 12 months

Briacell Therapeutics share dividends

We're not expecting Briacell Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Have Briacell Therapeutics's shares ever split?

Briacell Therapeutics's shares were split on a 1:300 basis on 2 January 2020. So if you had owned 300 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Briacell Therapeutics shares – just the quantity. However, indirectly, the new 29900% higher share price could have impacted the market appetite for Briacell Therapeutics shares which in turn could have impacted Briacell Therapeutics's share price.

Briacell Therapeutics share price volatility

Over the last 12 months, Briacell Therapeutics's shares have ranged in value from as little as $4.06 up to $12.47. A popular way to gauge a stock's volatility is its "beta".

BCTX.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Briacell Therapeutics's is 1.3241. This would suggest that Briacell Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Briacell Therapeutics's beta into context you can compare it against those of similar companies.

Briacell Therapeutics overview

BriaCell Therapeutics Corp. , a clinical stage immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to investigate the mechanism of action of novel off-the-shelf personalized therapeutics for cancer. The company is headquartered in West Vancouver, Canada. .

Frequently asked questions

What percentage of Briacell Therapeutics is owned by insiders or institutions?
Currently 25.004% of Briacell Therapeutics shares are held by insiders and 20.768% by institutions.
How many people work for Briacell Therapeutics?
Latest data suggests 5 work at Briacell Therapeutics.
When does the fiscal year end for Briacell Therapeutics?
Briacell Therapeutics's fiscal year ends in July.
Where is Briacell Therapeutics based?
Briacell Therapeutics's address is: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
What is Briacell Therapeutics's ISIN number?
Briacell Therapeutics's international securities identification number is: CA10778Y3023

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site